Thomas Wiegel
Pulmonary and Respiratory Medicine · 2009–2020
A researcher in the Science corpus: 12 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Pulmonary and Respiratory Medicine — 282 citations into it
- Oncology — 99 citations into it
Whom Thomas Wiegel trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- A. Billis (in Pulmonary and Respiratory Medicine)
Papers from Thomas Wiegel's perspective
Ordered by how strongly the researchers Thomas Wiegel trusts endorse each paper. Same corpus, a different order for every researcher.
- Screening and prostate-cancer mortality in a randomized European study. (New England Journal of Medicine)
- Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. (New England Journal of Medicine)
- Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. (New England Journal of Medicine)
- Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. (Journal of Clinical Oncology)
- Comparative effectiveness of minimally invasive vs open radical prostatectomy. (Journal of the American Medical Association (JAMA))
- Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. (European Urology)
- International variation in prostate cancer incidence and mortality rates. (European Urology)
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer (New England Journal of Medicine)
- Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. (Journal of the National Cancer Institute)
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer (Science)
Their papers
- Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. (2014) — 903 citations
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. (2020) — 2,673 citations
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. (2020) — 930 citations
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. (2017) — 1,488 citations
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. (2017) — 2,938 citations
- EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. (2014) — 2,039 citations
- EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. (2014) — 712 citations
- Guidelines on Prostate Cancer (2013) — 955 citations
- [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. (2011) — 883 citations
- EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. (2011) — 1,175 citations
- EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. (2011) — 1,458 citations
- Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. (2009) — 823 citations